a nonsignificant trendP = 0.18
The authors found no evidence that use of rATG was associated with PTLD, although there was a nonsignificant trend to more PTLD when rATG dose was 7.5 mg/kg or higher (1.55% vs. 0.50% with lower doses, P = 0.18) and the rate of PTLD was highest (2.62%) in heart transplant patients given rATG ≥7.5 mg/kg with no antiviral prophylaxis [ 70 ].